Bio-Techne Corp.
(NASDAQ : TECH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.31%324.210.0%$4670.09m
BNTXBioNTech SE -1.06%247.680.0%$730.32m
NVAXNovavax, Inc. -4.59%161.9579.4%$715.24m
AMGNAmgen, Inc. 0.51%207.841.4%$575.65m
SNSSSunesis Pharmaceuticals, Inc. -7.57%6.470.7%$452.28m
GILDGilead Sciences, Inc. -0.76%67.631.0%$426.45m
REGNRegeneron Pharmaceuticals, Inc. -0.43%553.242.7%$408.99m
ILMNIllumina, Inc. 0.45%409.933.3%$392.87m
CCXIChemoCentryx, Inc. -7.04%34.472.9%$387.64m
XLRNAcceleron Pharma, Inc. 0.50%172.945.3%$345.45m
VRTXVertex Pharmaceuticals, Inc. -0.07%181.771.9%$259.59m
BIIBBiogen, Inc. -1.43%281.191.7%$243.39m
OCGNOcugen, Inc. -13.83%8.660.0%$178.37m
XENEXenon Pharmaceuticals, Inc. 2.12%33.660.4%$178.19m
JSPRJasper Therapeutics, Inc. 31.57%16.420.0%$158.53m

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.